男性生育手术围术期阿片类药物处方与新发持续性阿片使用相关:大型理赔数据库回顾性分析
基于2010至2021年理赔数据库的回顾性队列研究,纳入387,565例接受男性生育手术的阿片初治男性,25.1%接受围术期阿片处方;倾向评分匹配后97,215例中,接受处方者新发持续性阿片使用为4.7%,未接受者为2.2%(风险比2.16,95%CI 2.05-2.27,需伤害人数39)。
要点
- 男性生育手术中25.1%接受围术期阿片处方。
- 匹配后新发持续性阿片使用:处方组4.7% vs 未处方组2.2%(RR 2.16)。
- 所有手术类型中,围术期阿片处方均与新发持续性阿片使用风险升高相关。
核心结论
- 男性生育手术后阿片处方与新发持续性阿片使用的显著风险相关,强调对男性生育手术审慎开具阿片处方的重要性。
研究设计与样本
- 使用链接电子病历数据与理赔的数据库的回顾性队列研究,纳入2010至2021年接受生育手术的阿片初治男性。
- 手术包括开放或腹腔镜精索静脉结扎术、精液囊肿切除术、睾丸切除或切开活检,且指数手术后2年内无Further需麻醉的手术干预。
- 有与无围术期阿片处方者按年龄、种族/族裔、吸烟状态、心理健康诊断和术前疼痛诊断进行倾向评分匹配。
主要发现
- 共识别387,565例接受生育手术的男性,其中25.1%接受阿片处方。
- 倾向评分匹配后纳入97,215例男性,接受围术期阿片处方者新发持续性阿片使用为4.7%,未接受者为2.2%(风险比2.16,95%置信区间2.05-2.27,需伤害人数39)。
- 独立评估每种生育手术时,接受围术期阿片类药物的男性在所有手术类型中新发持续性阿片使用的比值均统计学更高。
- 新发持续性阿片使用男性较无新发持续性阿片使用男性更可能继续发展为 prolonged 阿片使用。
关键数值与推荐
- 主要结局为新发持续性阿片使用(指数生育手术后3-9个月阿片处方)。
- 次要结局为 prolonged 阿片使用(指数生育手术后9-24个月阿片处方)。
临床怎么用
- 原文结论强调对男性生育手术审慎开具阿片处方的重要性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the risk of new persistent opioid use in opioid-naïve men who underwent male fertility procedures. DESIGN: Retrospective cohort study using a claims database. SETTING: A database linking electronic medical record data and claims-assessing men who underwent fertility procedures between 2010 and 2021. PATIENT(S): Opioid-naïve men who underwent fertility procedures (open or laparoscopic varicocelectomy, spermatocele excision, and testicular excisional or incisional biopsy) without further surgical intervention requiring anesthesia in the 2 years after the index procedure. Those with and without perioperative opioid prescriptions were propensity score matched on age, race/ethnicity, smoking status, mental health diagnoses, and preoperative pain diagnoses. INTERVENTION(S): Perioperative opioid prescription. MAIN OUTCOME MEASURE(S): The primary outcome was the incidence of new persistent opioid use (opioid prescription 3-9 months after the index fertility procedure). The secondary outcome was prolonged opioid use (opioid prescription 9-24 months after the index fertility procedure). RESULT(S): A total of 387,565 men who underwent fertility procedures were identified, of whom 25.1% received an opioid prescription. After propensity score matching, 97,215 men were included; 4.7% of men who received a perioperative opioid prescription developed new persistent opioid use compared with 2.2% of those without a perioperative opioid prescription (risk ratio, 2.16; 95% confidence interval, 2.05-2.27; number needed to harm, 39). When assessing each unique fertility procedure independently, men who received perioperative opioids had statistically higher odds of developing new persistent opioid use for all procedure types. Men with new persistent opioid use were much more likely to go on and develop prolonged opioid use than men without new persistent opioid use. CONCLUSION(S): Opioid prescription after male fertility procedures is associated with a significant risk of new persistent opioid use, emphasizing the importance of judicious opioid prescribing for male fertility procedures.
引用
- Able CA, Gabrielson AT, Meilchen C, et al. Perioperative opioid prescribing after male fertility procedures is associated with new persistent opioid use: retrospective analysis of a large claims database. Fertil Steril. 2022. PMID: 36529185. doi:10.1016/j.fertnstert.2022.12.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。